JPWO2022268192A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022268192A5
JPWO2022268192A5 JP2023579158A JP2023579158A JPWO2022268192A5 JP WO2022268192 A5 JPWO2022268192 A5 JP WO2022268192A5 JP 2023579158 A JP2023579158 A JP 2023579158A JP 2023579158 A JP2023579158 A JP 2023579158A JP WO2022268192 A5 JPWO2022268192 A5 JP WO2022268192A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
chain variable
ccr8
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527288A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/101000 external-priority patent/WO2022268192A1/en
Publication of JP2024527288A publication Critical patent/JP2024527288A/ja
Publication of JPWO2022268192A5 publication Critical patent/JPWO2022268192A5/ja
Pending legal-status Critical Current

Links

JP2023579158A 2021-06-25 2022-06-24 抗ｃｃｒ８抗体及びその使用 Pending JP2024527288A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/102324 2021-06-25
CNPCT/CN2021/102324 2021-06-25
CNPCT/CN2022/092803 2022-05-13
CNPCT/CN2022/092803 2022-05-13
PCT/CN2022/101000 WO2022268192A1 (en) 2021-06-25 2022-06-24 Anti-ccr8 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024527288A JP2024527288A (ja) 2024-07-24
JPWO2022268192A5 true JPWO2022268192A5 (enrdf_load_stackoverflow) 2025-07-02

Family

ID=84544143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579158A Pending JP2024527288A (ja) 2021-06-25 2022-06-24 抗ｃｃｒ８抗体及びその使用

Country Status (8)

Country Link
US (1) US20240352134A1 (enrdf_load_stackoverflow)
EP (1) EP4359442A1 (enrdf_load_stackoverflow)
JP (1) JP2024527288A (enrdf_load_stackoverflow)
KR (1) KR20240025013A (enrdf_load_stackoverflow)
CN (1) CN117616046A (enrdf_load_stackoverflow)
AU (1) AU2022298850A1 (enrdf_load_stackoverflow)
TW (1) TW202325732A (enrdf_load_stackoverflow)
WO (1) WO2022268192A1 (enrdf_load_stackoverflow)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
CN117285627B (zh) * 2023-09-06 2024-06-14 百济神州(上海)生物科技有限公司 抗ccr8抗体及其用途
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
CN119080936B (zh) * 2024-10-24 2025-05-23 百济神州(上海)生物科技有限公司 抗ccr8抗体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
CN110835371A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8单克隆抗体及其应用
TW202202521A (zh) * 2020-03-23 2022-01-16 美商必治妥美雅史谷比公司 用於治療癌症之抗ccr8抗體

Similar Documents

Publication Publication Date Title
JP2022177090A5 (enrdf_load_stackoverflow)
RU2766094C2 (ru) Антитела, нацеленные на антиген созревания в-клеток, и способы их применения
RU2021110369A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
JP2020533311A5 (ja) ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質
CN115003333A (zh) Pvrig结合蛋白及其医药用途
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2020514277A5 (enrdf_load_stackoverflow)
CN115605511A (zh) 抗tigit的抗体、其制备方法和应用
RU2012112829A (ru) Анти-gitr-антитела
JP2021508707A5 (enrdf_load_stackoverflow)
RU2010132956A (ru) Ангиопоэтин-2-специфические связывающие агенты
JP2023093753A5 (enrdf_load_stackoverflow)
RU2020130795A (ru) Нейтрализующие антитела к env вич-1 и их применение
JP2024024114A5 (enrdf_load_stackoverflow)
JP2020515277A5 (enrdf_load_stackoverflow)
JP2020513759A5 (enrdf_load_stackoverflow)
JP2020502233A5 (enrdf_load_stackoverflow)
RU2019121106A (ru) Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
JPWO2020033587A5 (enrdf_load_stackoverflow)
JP2016529213A5 (enrdf_load_stackoverflow)
JPWO2022268192A5 (enrdf_load_stackoverflow)
JPWO2020033630A5 (enrdf_load_stackoverflow)
RU2005121669A (ru) Анти-nogo антитела ("11с7") и их фармацевтическое использование
JPWO2020033664A5 (enrdf_load_stackoverflow)
JPWO2022111425A5 (enrdf_load_stackoverflow)